- Home
- XRX vs FBRX Comparison
XRX vs FBRX Comparison
Compare XRX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XRX | FBRX |
|---|---|---|
| Founded | 1906 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.1M | 487.2M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XRX | FBRX |
|---|---|---|
| Price | $3.18 | $21.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 4.9M | 365.5K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | 23.26 | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $117,000,000.00 | $36,000.00 |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.19 | $9.12 |
| 52 Week High | $6.80 | $35.80 |
Technical Indicators
Market Signals| Indicator | XRX | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 59.08 |
| Support Level | $2.97 | $19.03 |
| Resistance Level | $3.81 | $22.84 |
| Average True Range (ATR) | 0.25 | 1.43 |
| MACD | -0.05 | 0.74 |
| Stochastic Oscillator | 31.06 | 84.72 |
Price Performance
Historical ComparisonAbout XRX Xerox Holdings Corporation
Xerox Holdings Corp is a workplace technology company, building and integrating services-led, software-enabled, workplace solutions for enterprises large and small. It provide advance document technology, services, software, and integrated IT infrastructure solutions for a range of customers including small and mid-sized businesses, large enterprises, governments and graphic communications providers, and for partners who serve them. Xerox serves customers globally in North America, Europe, Latin America, Brazil, Asia Pacific (APAC), the Middle East, Africa, and India.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.